Ann: GENERAL: PEB: PE signs agreement with Americ

• Release Date: 22/10/13 12:34
• Summary: GENERAL: PEB: PE signs agreement with America's Choice Provider Network
• Price Sensitive: No
• Download Document  5.32KB

					PEB
22/10/2013 10:34
GENERAL

REL: 1034 HRS Pacific Edge Limited

GENERAL: PEB: PE signs agreement with America's Choice Provider Network

22 October 2013

Pacific Edge signs agreement with America's Choice Provider Network to expand
access to Cxbladder in the US

Pacific Edge has signed an agreement with America's Choice Provider Network
(ACPN) to provide more Americans access to Cxbladder. ACPN offers a medical
network solution for more than 14 million Americans through its client base
consisting of insurance carriers, third party administrators, health and
welfare funds, employer groups and self-insured health plans. This follows
Pacific Edge's recent announcement of the agreement with FedMed providing 40
million Americans with access to Cxbladder1.

Pacific Edge Chief Executive Officer David Darling says agreements with
FedMed and now ACPN form key elements in the commercial roll-out of Cxbaldder
in the US.
Pacific Edge through its wholly owned subsidiary Pacific Edge Diagnostics USA
(PEDUSA) has already achieved the first commercial sales of Cxbladder in the
US2 and has processed samples collected using its proprietary Urine Sample
System at its custom built laboratory in Hershey, Pennsylvania.

"These provider networks provide patients access to healthcare services and
technology by contracting with providers and payers on a national basis.
These two recent agreements signed with FedMed and now ACPN will give
millions of Americans access to Cxbladder and its positive benefits as a
quick, cost effective, non-invasive and highly accurate cancer detection test
that is particularly appealing to US healthcare professionals, patients, and
insurers" said Jackie Walker, Chief Executive Officer of PEDUSA.

"PEDUSA's sales and marketing team is focussed on the clinicians who are
treating the largest number of bladder cancer patients. They are also
focussed on the large commercial payers and the Centre for Medicare and
Medicaid Services (CMS), which provides healthcare insurance for 100 million
people or nearly a third of the American population.  Other key sales targets
include Integrated Healthcare Systems, comprising many providers and
facilities while offering a wide variety of health insurance plans, the
Veterans Administration (VA), and Large Urology Groups (LUGS), who are the
point of contact for many patients presenting with haematuria (blood in the
urine) which is an early indicator of possible bladder cancer".

More than one million Americans will undergo medical investigation this year
for potential bladder cancer at an estimated cost of $US1 billion. Bladder
cancer is one of the most expensive cancers to treat.  The very high
recurrence of this disease, requiring some patients to receive expensive
monitoring for the rest of their lives, causes bladder cancer to have the
highest total medical costs of any cancer from detection to death. In the US,
the total medical cost approaches $US220,000 per patient.

1
http://www.pacificedge.co.nz/news-and-media/news/pacific-edge-agreement-with-
national-provider-network-fedmed-gives-40-million-americans-access-to-cxbladd
er/

2
http://www.pacificedgedx.com/news-and-media/news/first-commercial-sales-achie
ved-for-pacific-edges-cxbladder-in-the-usa/

For more information contact:

David Darling
Chief Executive Officer
Pacific Edge Ltd
P: +64 (3) 479 5800

ABOUT PACIFIC EDGE

Pacific Edge Limited (NZX: PEB) is a New Zealand based cancer diagnostic
company specialising in the discovery and commercialisation of diagnostic and
prognostic technology for the early detection and monitoring of cancer.

Products in development and in clinical trials are accurate and simple to use
genomic and proteomic tools for the earlier detection, improved
characterisation and better management of gastric, bladder, colorectal
cancers and melanoma. The company has recently completed and released its
first product for the detection of bladder cancer, Cxbladder, and is actively
marketing the product to urologists in New Zealand, Australia and soon to be
Spain and the US.

www.pacificedge.co.nz

ABOUT PACIFIC EDGE DIAGNOSTICS

Pacific Edge takes its exciting cancer detection tests to market through its
wholly owned subsidiaries, Pacific Edge Diagnostics NZ Ltd and Pacific Edge
Diagnostics USA Ltd, and selected commercial partners in Australia and Spain,
Healthscope and Oryzon respectively.

www.pacificedgedx.com

ABOUT Cxbladder

Cxbladder is a proprietary, accurate molecular diagnostic test that enables
the non-invasive detection of bladder cancer from a small volume of urine. It
provides general practitioners and urologists with a quick, cost effective
and accurate measure of the presence of the cancer, and provides urologists
with the opportunity to reduce their reliance on the need for invasive tests
such as cystoscopy. The recently published, Journal of Urology in September
2012, multi-centre international clinical study recruited 485 patients from
Australia and New Zealand.

Results show that Cxbladder out-performed all of the benchmark technologies
in the clinical trial and detected nearly all of the tumours of concern to a
urologist; At a performance of 82% sensitivity and 85% specificity the test
sees 100% of T1, 100% of T2, 100% of T3, 100% of Tis and 100% of upper
urinary tract cancers as well as greater than 95% of high grade tumours.

www.cxbladder.com
End CA:00242697 For:PEB    Type:GENERAL    Time:2013-10-22 10:34:35